These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 36295854)

  • 21. Partial external biliary diversion in children with progressive familial intrahepatic cholestasis and Alagille disease.
    Yang H; Porte RJ; Verkade HJ; De Langen ZJ; Hulscher JB
    J Pediatr Gastroenterol Nutr; 2009 Aug; 49(2):216-21. PubMed ID: 19561545
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progressive Familial Intrahepatic Cholestasis: A Study in Children From a Liver Transplant Center in India.
    Mehta S; Kumar K; Bhardwaj R; Malhotra S; Goyal N; Sibal A
    J Clin Exp Hepatol; 2022; 12(2):454-460. PubMed ID: 35535061
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial.
    Thompson RJ; Arnell H; Artan R; Baumann U; Calvo PL; Czubkowski P; Dalgic B; D'Antiga L; Durmaz Ö; Fischler B; Gonzalès E; Grammatikopoulos T; Gupte G; Hardikar W; Houwen RHJ; Kamath BM; Karpen SJ; Kjems L; Lacaille F; Lachaux A; Lainka E; Mack CL; Mattsson JP; McKiernan P; Özen H; Rajwal SR; Roquelaure B; Shagrani M; Shteyer E; Soufi N; Sturm E; Tessier ME; Verkade HJ; Horn P
    Lancet Gastroenterol Hepatol; 2022 Sep; 7(9):830-842. PubMed ID: 35780807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term outcomes after cholecystocolostomy for progressive familial intrahepatic cholestasis.
    Chen L; Xiao H; Ren XH; Li L
    Hepatol Res; 2018 Dec; 48(13):1163-1171. PubMed ID: 29934967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Surgical versus Medical Management of Progressive Familial Intrahepatic Cholestasis-Case Compilation and Review of the Literature.
    Hüpper MN; Pichler J; Huber WD; Heilos A; Schaup R; Metzelder M; Langer S
    Children (Basel); 2023 May; 10(6):. PubMed ID: 37371180
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis.
    Luo Y; Decato BE; Charles ED; Shevell DE; McNaney C; Shipkova P; Apfel A; Tirucherai GS; Sanyal AJ
    JHEP Rep; 2022 Jan; 4(1):100392. PubMed ID: 34977519
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: Phase 2 study.
    Baumann U; Sturm E; Lacaille F; Gonzalès E; Arnell H; Fischler B; Jørgensen MH; Thompson RJ; Mattsson JP; Ekelund M; Lindström E; Gillberg PG; Torfgård K; Soni PN
    Clin Res Hepatol Gastroenterol; 2021 Sep; 45(5):101751. PubMed ID: 34182185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progressive familial intrahepatic cholestasis.
    Srivastava A
    J Clin Exp Hepatol; 2014 Mar; 4(1):25-36. PubMed ID: 25755532
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autoimmune BSEP disease: disease recurrence after liver transplantation for progressive familial intrahepatic cholestasis.
    Kubitz R; Dröge C; Kluge S; Stross C; Walter N; Keitel V; Häussinger D; Stindt J
    Clin Rev Allergy Immunol; 2015 Jun; 48(2-3):273-84. PubMed ID: 25342496
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the role of bile acids and serotonin as markers of pruritus in children with chronic cholestatic liver disease.
    Koofy NE; Yassin N; Okasha S; William H; Elakel W; Elshiwy Y
    Arab J Gastroenterol; 2021 Sep; 22(3):199-202. PubMed ID: 34090830
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world experience of maralixibat in Alagille syndrome: Novel findings outside of clinical trials.
    Himes R; Rosenthal P; Dilwali N; Smith K; Venick R; Gonzalez-Peralta RP
    J Pediatr Gastroenterol Nutr; 2024 Mar; 78(3):506-513. PubMed ID: 38334237
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maralixibat Treatment Response in Alagille Syndrome is Associated with Improved Health-Related Quality of Life.
    Kamath BM; Goldstein A; Howard R; Garner W; Vig P; Marden JR; Billmyer E; Anderson A; Kirson N; Jacquemin E; Gonzales E
    J Pediatr; 2023 Jan; 252():68-75.e5. PubMed ID: 36096175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suppression of bile acid synthesis as a tipping point in the disease course of primary sclerosing cholangitis.
    Braadland PR; Schneider KM; Bergquist A; Molinaro A; Lövgren-Sandblom A; Henricsson M; Karlsen TH; Vesterhus M; Trautwein C; Hov JR; Marschall HU
    JHEP Rep; 2022 Nov; 4(11):100561. PubMed ID: 36176935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two Case Reports of Successful Treatment of Cholestasis With Steroids in Patients With PFIC-2.
    Engelmann G; Wenning D; Herebian D; Sander O; Dröge C; Kluge S; Kubitz R
    Pediatrics; 2015 May; 135(5):e1326-32. PubMed ID: 25847799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ileal Bile Acid Transporter Blockers for Cholestatic Liver Disease in Pediatric Patients with Alagille Syndrome: A Systematic Review and Meta-Analysis.
    Muntaha HST; Munir M; Sajid SH; Sarfraz Z; Sarfraz A; Robles-Velasco K; Sarfraz M; Felix M; Cherrez-Ojeda I
    J Clin Med; 2022 Dec; 11(24):. PubMed ID: 36556142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bile salt export pump-reactive antibodies form a polyclonal, multi-inhibitory response in antibody-induced bile salt export pump deficiency.
    Stindt J; Kluge S; Dröge C; Keitel V; Stross C; Baumann U; Brinkert F; Dhawan A; Engelmann G; Ganschow R; Gerner P; Grabhorn E; Knisely AS; Noli KA; Pukite I; Shepherd RW; Ueno T; Schmitt L; Wiek C; Hanenberg H; Häussinger D; Kubitz R
    Hepatology; 2016 Feb; 63(2):524-37. PubMed ID: 26516723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Longitudinal profiles of 15 serum bile acids in patients with intrahepatic cholestasis of pregnancy.
    Tribe RM; Dann AT; Kenyon AP; Seed P; Shennan AH; Mallet A
    Am J Gastroenterol; 2010 Mar; 105(3):585-95. PubMed ID: 19904249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Absence of Bsep/Abcb11 attenuates MCD diet-induced hepatic steatosis but aggravates inflammation in mice.
    Fuchs CD; Krivanec S; Steinacher D; Mlitz V; Wahlström A; Stahlman M; Claudel T; Scharnagl H; Stojakovic T; Marschall HU; Trauner M
    Liver Int; 2020 Jun; 40(6):1366-1377. PubMed ID: 32141703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systemic ASBT inactivation protects against liver damage in obstructive cholestasis in mice.
    Kunst RF; de Waart DR; Wolters F; Duijst S; Vogels EW; Bolt I; Verheij J; Beuers U; Oude Elferink RPJ; van de Graaf SFJ
    JHEP Rep; 2022 Nov; 4(11):100573. PubMed ID: 36160754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcomes of surgical management of familial intrahepatic cholestasis 1 and bile salt export protein deficiencies.
    Bull LN; Pawlikowska L; Strautnieks S; Jankowska I; Czubkowski P; Dodge JL; Emerick K; Wanty C; Wali S; Blanchard S; Lacaille F; Byrne JA; van Eerde AM; Kolho KL; Houwen R; Lobritto S; Hupertz V; McClean P; Mieli-Vergani G; Sokal E; Rosenthal P; Whitington PF; Pawlowska J; Thompson RJ
    Hepatol Commun; 2018 May; 2(5):515-528. PubMed ID: 29761168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.